Merck's KEYTRUDA® Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer Life Science Investing
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc. Life Science Investing
Veklury® Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations Pharmaceutical Investing
Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023 Pharmaceutical Investing
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27 Life Science Investing
FDA Accepts Application for Merck's KEYTRUDA® Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Life Science Investing
Boosh Plant-Based Brands Inc. Announces Engagement with Storied Health Partners and Debt Settlement Life Science Investing
CORRECTION FROM SOURCE: Correction of the Press Releases Dated January 9, 2023 and March 14, 2023 Life Science Investing
AbbVie Invites College Students Living with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2023-2024 Academic School Year Pharmaceutical Investing
